AiPD: Autoinhibited Protein Database

O00762

Gene name	UBE2C (UBCH10)
Protein name	Ubiquitin-conjugating enzyme E2 C
Names	(E3-independent) E2 ubiquitin-conjugating enzyme C, E2 ubiquitin-conjugating enzyme C, UbcH10, Ubiquitin carrier protein C, Ubiquitin-protein ligase C
Species	Homo sapiens (Human)
KEGG Pathway	hsa:11065
EC number	2.3.2.23: Aminoacyltransferases
Protein Class

Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

1-65 (Predicted disordered autoinhibitory region) PR

Target domain
Relief mechanism
Assay	cis-regPred

AID

1-65 (Predicted disordered autoinhibitory region)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

References

Yeon JH et al. (2016) "Systems-wide Identification of cis-Regulatory Elements in Proteins", Cell Systems, 2, 89-100

Autoinhibited structure

Activated structure

8 structures for O00762

Entry ID	Method	Resolution	Chain	Position	Source
1I7K	X-ray	195 A	A/B	1-179	PDB
4YII	X-ray	180 A	U	27-179	PDB
5A31	EM	430 A	Q	29-173	PDB
5KHR	EM	610 A	Q	1-179	PDB
5L9U	EM	640 A	U	1-179	PDB
8TAR	EM	400 A	Q	29-173	PDB
8TAU	EM	350 A	Q	1-179	PDB
AF-O00762-F1	Predicted				AlphaFoldDB

148 variants for O00762

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
CA409185301 rs1225528823	3	S>F		No	ClinGen TOPMed gnomAD
rs984421119 CA315616073	5	N>T		No	ClinGen gnomAD
rs561525053 CA315616091	6	R>G		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
CA9880537 rs561525053	6	R>S		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
rs867231207 CA315616095	7	D>A		No	ClinGen Ensembl
CA409185340 rs763421388	10	A>P		No	ClinGen ExAC TOPMed gnomAD
rs763421388 CA9880539	10	A>S		No	ClinGen ExAC TOPMed gnomAD
rs763421388 CA315616099	10	A>T		No	ClinGen ExAC TOPMed gnomAD
TCGA novel	11	T>missing	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA409185349 rs1243957339	11	T>I		No	ClinGen TOPMed gnomAD
rs1202446446 CA409185346	11	T>S		No	ClinGen TOPMed gnomAD
rs1222721494 CA409185356	12	S>R		No	ClinGen TOPMed
CA409185364 rs766882355	14	A>P		No	ClinGen ExAC TOPMed gnomAD
rs766882355 CA409185365	14	A>S		No	ClinGen ExAC TOPMed gnomAD
rs766882355 CA9880540	14	A>T		No	ClinGen ExAC TOPMed gnomAD
CA409185366 rs1186759513	14	A>V		No	ClinGen gnomAD
rs1392036860 CA409185369	15	A>T		No	ClinGen gnomAD
rs1271204292 CA409185377	16	A>S		No	ClinGen TOPMed
rs1429651798 CA409185380	16	A>V		No	ClinGen gnomAD
rs774646356 CA9880541	17	R>C		No	ClinGen ExAC TOPMed gnomAD
rs774646356 CA409185382	17	R>G		No	ClinGen ExAC TOPMed gnomAD
CA409185385 rs1376325872	17	R>L		No	ClinGen gnomAD
rs1337052897 CA409185398	19	G>E		No	ClinGen gnomAD
CA409185394 rs1467881661	19	G>R		No	ClinGen gnomAD
CA409185401 rs1601038029	20	A>T		No	ClinGen Ensembl
rs1387449323 CA409185414	22	P>S		No	ClinGen gnomAD
CA9880543 rs11537645	23	S>R		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA409185428 rs761413591	24	G>R		No	ClinGen ExAC gnomAD
rs1368653521 CA409185430	24	G>V		No	ClinGen TOPMed
rs761413591 CA9880545	24	G>W		No	ClinGen ExAC gnomAD
VAR_007694	25	G>D		No	UniProt
CA409185438 rs1386174145	26	A>T	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
rs749925974 CA9880548	27	A>P		No	ClinGen ExAC TOPMed gnomAD
CA409185444 rs749925974	27	A>S		No	ClinGen ExAC TOPMed gnomAD
CA9880547 rs749925974	27	A>T		No	ClinGen ExAC TOPMed gnomAD
rs1223889210 CA409185449	28	R>W		No	ClinGen gnomAD
rs1267182417 CA409185467	31	V>L		No	ClinGen TOPMed gnomAD
rs1267182417 CA409185465	31	V>M		No	ClinGen TOPMed gnomAD
CA409185474 rs1356214083	32	G>D		No	ClinGen TOPMed gnomAD
rs1207003316 CA409185471	32	G>S		No	ClinGen gnomAD
CA409185475 rs1356214083	32	G>V		No	ClinGen TOPMed gnomAD
rs761500077 CA9880565	36	Q>E		No	ClinGen ExAC TOPMed gnomAD
rs1190657829 CA409185517	37	Q>*		No	ClinGen gnomAD
rs1258952908 CA409185523	38	E>K	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed
rs1207386492 CA409185532	39	L>V		No	ClinGen TOPMed
CA409185543 rs1269104737	40	M>I		No	ClinGen TOPMed
rs138058971 CA9880566	40	M>V		No	ClinGen ESP ExAC TOPMed gnomAD
CA409185549 rs1423586972	41	T>I	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
CA409185547 rs1423586972	41	T>N		No	ClinGen gnomAD
rs1223941923 CA409185558	43	M>L		No	ClinGen gnomAD
rs545175408 CA9880567	43	M>T		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
CA409185557 rs1223941923	43	M>V		No	ClinGen gnomAD
CA9880588 rs766016081	47	D>N		No	ClinGen ExAC TOPMed gnomAD
CA409185647 rs1189026288	54	P>S		No	ClinGen TOPMed
CA315617320 rs377081477	56	S>*		No	ClinGen ESP TOPMed
rs144831911 CA9880589	57	D>N		No	ClinGen 1000Genomes ExAC gnomAD
CA9880590 rs759589512	59	L>F		No	ClinGen ExAC TOPMed gnomAD
CA409185688 rs1174298561	60	F>S		No	ClinGen gnomAD
rs767562250 CA9880591	62	W>C		No	ClinGen ExAC gnomAD
CA9880592 rs752601468	64	G>A		No	ClinGen ExAC gnomAD
CA409185731 rs1225404499	66	I>M		No	ClinGen TOPMed
CA409185733 rs1319994180	67	H>D		No	ClinGen gnomAD
CA409185737 rs1433546288	67	H>Q		No	ClinGen gnomAD
CA315617334 rs956674941	67	H>R		No	ClinGen TOPMed gnomAD
rs1319994180 CA409185734	67	H>Y		No	ClinGen gnomAD
CA409185750 rs1271262675	69	A>V		No	ClinGen gnomAD
rs779653538 CA9880649	73	V>L		No	ClinGen ExAC gnomAD
rs746495033 CA9880650	74	Y>*		No	ClinGen ExAC gnomAD
rs768695868 CA9880651	75	E>D		No	ClinGen ExAC gnomAD
rs1448910805 CA409186132	77	L>P		No	ClinGen gnomAD
CA9880652 rs547850953	78	R>S		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
CA9880653 rs761667583	79	Y>F		No	ClinGen ExAC TOPMed gnomAD
CA9880654 rs769604009	80	K>*		No	ClinGen ExAC gnomAD
rs772939191 CA9880655	80	K>N		No	ClinGen ExAC gnomAD
rs763209065 CA9880656	82	S>L	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA gnomAD
CA9880658 rs751722028	84	E>D		No	ClinGen ExAC TOPMed gnomAD
rs371616231 CA9880660	86	P>H		No	ClinGen ESP ExAC TOPMed gnomAD
rs759551578 CA9880659	86	P>T		No	ClinGen ExAC gnomAD
CA9880661 rs753288094	87	S>G		No	ClinGen ExAC TOPMed gnomAD
CA9880662 rs756640882	87	S>R		No	ClinGen ExAC gnomAD
CA9880664 rs754226233	89	Y>*		No	ClinGen ExAC
rs778333049 CA9880663	89	Y>S		No	ClinGen ExAC gnomAD
rs374439898 CA315618202	90	P>A		No	ClinGen ESP
rs758135325 CA9880665	92	N>S		No	ClinGen ExAC TOPMed gnomAD
rs367706641 CA9880668	95	T>A		No	ClinGen ESP ExAC gnomAD
rs367706641 CA409186238	95	T>S		No	ClinGen ESP ExAC gnomAD
CA9880669 rs780709357	96	V>M		No	ClinGen ExAC gnomAD
CA9880671 rs769693911	97	K>N		No	ClinGen ExAC gnomAD
CA315618220 rs976266522	97	K>R		No	ClinGen TOPMed
CA409186268 rs1198408107	100	T>A		No	ClinGen gnomAD
CA9880672 COSM1027285 rs773029038	100	T>M	Variant assessed as Somatic; 0.0 impact. endometrium [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated ExAC NCI-TCGA gnomAD
CA409186278 rs1254022907	101	P>L		No	ClinGen TOPMed gnomAD
rs932190109 CA315618263	103	Y>F		No	ClinGen TOPMed gnomAD
rs770704295 CA409186312	106	N>I		No	ClinGen ExAC TOPMed gnomAD
CA9880676 rs770704295	106	N>S	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
CA9880678 rs759764860	107	V>M		No	ClinGen ExAC TOPMed gnomAD
rs1225682574 CA409186331	109	T>N		No	ClinGen gnomAD
CA9880679 rs767520518	111	G>D		No	ClinGen ExAC gnomAD
rs761307294 CA9880683	115	L>P		No	ClinGen ExAC gnomAD
CA9880684 rs764691584	121	K>T		No	ClinGen ExAC gnomAD
CA315618299 rs1033161095	122	W>R		No	ClinGen Ensembl
rs1244942351 CA409186433	124	A>S		No	ClinGen TOPMed
TCGA novel	124	A>V	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA9880686 COSM188841 rs757572822	125	L>P	large_intestine Variant assessed as Somatic; impact. [Cosmic, NCI-TCGA]	No	ClinGen cosmic curated ExAC NCI-TCGA TOPMed gnomAD
rs757572822 CA9880687	125	L>Q		No	ClinGen ExAC TOPMed gnomAD
rs148799246 CA9880690	126	Y>C		No	ClinGen ESP ExAC TOPMed gnomAD
CA9880689 rs148799246	126	Y>F		No	ClinGen ESP ExAC TOPMed gnomAD
CA315618344 rs7352110	129	R>G		No	ClinGen Ensembl
rs371311367 CA409186469	130	T>N		No	ClinGen ESP ExAC TOPMed gnomAD
rs371311367 CA9880692	130	T>S		No	ClinGen ESP ExAC TOPMed gnomAD
CA315618347 rs201176918	131	I>M		No	ClinGen 1000Genomes
rs767584548 CA315618348	133	L>F		No	ClinGen Ensembl
rs777703076 CA9880693	136	Q>R		No	ClinGen ExAC TOPMed gnomAD
CA315618357 rs902257654	138	L>F		No	ClinGen TOPMed
rs1163401493 CA409186528	140	G>E		No	ClinGen TOPMed
CA315618441 rs1036918950	141	E>D		No	ClinGen Ensembl
rs1313636957 CA409186555	142	P>R		No	ClinGen gnomAD
rs142378082 CA315618445	145	D>N		No	ClinGen ESP TOPMed gnomAD
rs1274157914 CA409186591	146	S>N		No	ClinGen gnomAD
CA409186622 rs1272519354	150	T>K		No	ClinGen gnomAD
CA9880719 rs201125748	154	E>K		No	ClinGen ExAC TOPMed gnomAD
rs1198011557 CA409186654	155	L>I		No	ClinGen TOPMed
CA9880720 rs776802939	156	W>R		No	ClinGen ExAC gnomAD
rs762275535 CA9880721	157	K>E		No	ClinGen ExAC TOPMed gnomAD
rs770303252 CA9880722	157	K>R		No	ClinGen ExAC gnomAD
CA409186678 CA9880723 rs61760191	158	N>K		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
TCGA novel	158	N>T	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA9880724 rs763391914	159	P>T		No	ClinGen ExAC gnomAD
rs373084608 CA9880725	160	T>I		No	ClinGen ESP ExAC TOPMed gnomAD
CA409186704 rs774676127	161	A>G		No	ClinGen ExAC TOPMed gnomAD
rs752378234 CA9880726	161	A>P		No	ClinGen ExAC TOPMed gnomAD
rs752378234 CA409186689	161	A>T		No	ClinGen ExAC TOPMed gnomAD
CA9880744 rs774676127	161	A>V		No	ClinGen ExAC TOPMed gnomAD
CA409186734 rs1318325554	165	Y>F		No	ClinGen gnomAD
CA409186743 rs753350058	167	Q>*		No	ClinGen ExAC gnomAD
CA9880747 rs753350058	167	Q>E		No	ClinGen ExAC gnomAD
rs1029457888 CA315619068	167	Q>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen Ensembl NCI-TCGA
CA9880748 rs761402285	168	E>K		No	ClinGen ExAC
CA315619079 rs202149476	169	T>A		No	ClinGen 1000Genomes
CA409186755 rs202149476	169	T>P		No	ClinGen 1000Genomes
CA409186763 rs1568717224	170	Y>S		No	ClinGen Ensembl
rs955166544 CA315619099	173	Q>*		No	ClinGen TOPMed gnomAD
CA9880750 rs376878469	174	V>G		No	ClinGen ESP ExAC gnomAD
CA9880751 rs758357409	175	T>P		No	ClinGen ExAC gnomAD
CA409186809 rs1324101765	177	Q>*		No	ClinGen TOPMed gnomAD
rs766325761 CA9880752	177	Q>R		No	ClinGen ExAC gnomAD
CA409186820 rs1282135234	178	E>D		No	ClinGen gnomAD
rs985255663 CA315619134	178	E>G		No	ClinGen Ensembl

No associated diseases with O00762

2 regional properties for O00762

Type	Name	Position	InterPro Accession
domain	Ubiquitin-conjugating enzyme E2	30 - 175	IPR000608
active_site	Ubiquitin-conjugating enzyme, active site	103 - 118	IPR023313

Functions

		Description
EC Number	2.3.2.23	Aminoacyltransferases
Subcellular Localization
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category	No pathway information available

6 GO annotations of cellular component

Name	Definition
anaphase-promoting complex	A ubiquitin ligase complex that degrades mitotic cyclins and anaphase inhibitory protein, thereby triggering sister chromatid separation and exit from mitosis. Substrate recognition by APC occurs through degradation signals, the most common of which is termed the Dbox degradation motif, originally discovered in cyclin B.
cytosol	The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
nucleoplasm	That part of the nuclear content other than the chromosomes or the nucleolus.
nucleus	A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.
plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.
ubiquitin ligase complex	A protein complex that includes a ubiquitin-protein ligase and enables ubiquitin protein ligase activity. The complex also contains other proteins that may confer substrate specificity on the complex.

5 GO annotations of molecular function

Name	Definition
ATP binding	Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
ubiquitin conjugating enzyme activity	Isoenergetic transfer of ubiquitin from one protein to another via the reaction X-ubiquitin + Y -> Y-ubiquitin + X, where both the X-ubiquitin and Y-ubiquitin linkages are thioester bonds between the C-terminal glycine of ubiquitin and a sulfhydryl side group of a cysteine residue.
ubiquitin protein ligase activity	Catalysis of the transfer of ubiquitin to a substrate protein via the reaction X-ubiquitin + S -> X + S-ubiquitin, where X is either an E2 or E3 enzyme, the X-ubiquitin linkage is a thioester bond, and the S-ubiquitin linkage is an amide bond: an isopeptide bond between the C-terminal glycine of ubiquitin and the epsilon-amino group of lysine residues in the substrate or, in the linear extension of ubiquitin chains, a peptide bond the between the C-terminal glycine and N-terminal methionine of ubiquitin residues.
ubiquitin-like protein ligase binding	Binding to a ubiquitin-like protein ligase, such as ubiquitin-ligase.
ubiquitin-protein transferase activity	Catalysis of the transfer of ubiquitin from one protein to another via the reaction X-Ub + Y --> Y-Ub + X, where both X-Ub and Y-Ub are covalent linkages.

12 GO annotations of biological process

Name	Definition
anaphase-promoting complex-dependent catabolic process	The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, with ubiquitin-protein ligation catalyzed by the anaphase-promoting complex, and mediated by the proteasome.
cell division	The process resulting in division and partitioning of components of a cell to form more cells; may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells.
exit from mitosis	The cell cycle transition where a cell leaves M phase and enters a new G1 phase. M phase is the part of the mitotic cell cycle during which mitosis and cytokinesis take place.
free ubiquitin chain polymerization	The process of creating free ubiquitin chains, compounds composed of a large number of ubiquitin monomers. These chains are not conjugated to a protein.
positive regulation of exit from mitosis	Any process that activates or increases the rate of progression from anaphase/telophase (high mitotic CDK activity) to G1 (low mitotic CDK activity).
positive regulation of ubiquitin protein ligase activity	Any process that activates or increases the frequency, rate or extent of ubiquitin protein ligase activity.
protein K11-linked ubiquitination	A protein ubiquitination process in which ubiquitin monomers are attached to a protein, and then ubiquitin polymers are formed by linkages between lysine residues at position 11 of the ubiquitin monomers. K11-linked polyubiquitination targets the substrate protein for degradation. The anaphase-promoting complex promotes the degradation of mitotic regulators by assembling K11-linked polyubiquitin chains.
protein K48-linked ubiquitination	A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 48 of the ubiquitin monomers, is added to a protein. K48-linked ubiquitination targets the substrate protein for degradation.
protein polyubiquitination	Addition of multiple ubiquitin groups to a protein, forming a ubiquitin chain.
protein ubiquitination	The process in which one or more ubiquitin groups are added to a protein.
regulation of mitotic metaphase/anaphase transition	Any process that modulates the frequency, rate or extent of the cell cycle process in which a cell progresses from metaphase to anaphase during mitosis, triggered by the activation of the anaphase promoting complex by Cdc20/Sleepy homolog which results in the degradation of Securin.
ubiquitin-dependent protein catabolic process	The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of a ubiquitin group, or multiple ubiquitin groups, to the protein.

12 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
Q32PA5	UBE2C	Ubiquitin-conjugating enzyme E2 C	Bos taurus (Bovine)	PR
Q9H8T0	AKTIP	AKT-interacting protein	Homo sapiens (Human)	PR
Q9Y385	UBE2J1	Ubiquitin-conjugating enzyme E2 J1	Homo sapiens (Human)	PR
P61086	UBE2K	Ubiquitin-conjugating enzyme E2 K	Homo sapiens (Human)	PR
Q9NPD8	UBE2T	Ubiquitin-conjugating enzyme E2 T	Homo sapiens (Human)	PR
O14933	UBE2L6	Ubiquitin/ISG15-conjugating enzyme E2 L6	Homo sapiens (Human)	PR
Q96LR5	UBE2E2	Ubiquitin-conjugating enzyme E2 E2	Homo sapiens (Human)	PR
Q969T4	UBE2E3	Ubiquitin-conjugating enzyme E2 E3	Homo sapiens (Human)	PR
Q7Z7E8	UBE2Q1	Ubiquitin-conjugating enzyme E2 Q1	Homo sapiens (Human)	PR
A1L167	UBE2QL1	Ubiquitin-conjugating enzyme E2Q-like protein 1	Homo sapiens (Human)	PR
Q16763	UBE2S	Ubiquitin-conjugating enzyme E2 S	Homo sapiens (Human)	EV
Q9D1C1	Ube2c	Ubiquitin-conjugating enzyme E2 C	Mus musculus (Mouse)	PR

10	20	30	40	50	60
MASQNRDPAA	TSVAAARKGA	EPSGGAARGP	VGKRLQQELM	TLMMSGDKGI	SAFPESDNLF
70	80	90	100	110	120
KWVGTIHGAA	GTVYEDLRYK	LSLEFPSGYP	YNAPTVKFLT	PCYHPNVDTQ	GNICLDILKE
130	140	150	160	170
KWSALYDVRT	ILLSIQSLLG	EPNIDSPLNT	HAAELWKNPT	AFKKYLQETY	SKQVTSQEP